New DoD EHR system named GENESIS

Military Health System (MHS) officials say the Department of Defense's new EHR will be called MHS GENESIS and will launch at the end of calendar year 2016.  

According to a health.mil article, the DoD has purchased a state-of-the-art EHR to "support us in our mission to continue to provide high quality healthcare to our beneficiaries, as well as an agile, responsive system for our healthcare professionals." 

The military will begin implementing GENESIS in the Pacific Northwest at the end of this year, followed by a pre-planned, programmed installation expected to be completed over several years. The system will be available at any location throughout all DoD facilities, and accessible to all members of the DoD’s healthcare team. 

William M. Roberts, MD, MBA, a retired Navy rear admiral who serves as the MHS functional champion, told health.mil that the new EHR reflects a whole new way of doing business for the MHS. 

“We’ve looked at this process as finding what is best for the MHS as a whole, not just in individual areas,” said Roberts. “We see this as the latest step in making sure patients are able to be fully engaged in their own health.” 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.